906 related articles for article (PubMed ID: 19318378)
41. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
42. Treatment evaluation of liraglutide in type 2 diabetes.
Kela R; Davies MJ
Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
[TBL] [Abstract][Full Text] [Related]
43. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
Lüdemann J
MMW Fortschr Med; 2011 Jul; 153 Suppl 2():56-63. PubMed ID: 23964469
[TBL] [Abstract][Full Text] [Related]
45. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
Lund A; Knop FK; Vilsbøll T
Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
[TBL] [Abstract][Full Text] [Related]
46. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
47. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
Ottney A
Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
[TBL] [Abstract][Full Text] [Related]
48. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
Montanya E
Expert Opin Pharmacother; 2012 Jul; 13(10):1451-67. PubMed ID: 22725703
[TBL] [Abstract][Full Text] [Related]
49. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
[TBL] [Abstract][Full Text] [Related]
50. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
51. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
52. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
53. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
Madsbad S
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
[TBL] [Abstract][Full Text] [Related]
54. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
55. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
Bolli GB; Owens DR
Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
57. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
[TBL] [Abstract][Full Text] [Related]
58. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
Ross SA; Ballantine J
Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
[TBL] [Abstract][Full Text] [Related]
59. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
[TBL] [Abstract][Full Text] [Related]
60. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
